Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine

Population Pharmacokinetics of Gemcitabine and Its Metabolite in Japanese Cancer Patients

(2010) Emiko Sugiyama et al.   CLINICAL PHARMACOKINETICS

Ethnic Differences of two Non-synonymous Single Nucleotide Polymorphisms in CDA Gene

(2010) Emiko Sugiyama et al.   Drug Metabolism and Pharmacokinetics

Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism

(2010) Jan Gerard Maring et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Cytidine Deaminase Residual Activity in Serum Is a Predictive Marker of Early Severe Toxicities in Adults After Gemcitabine-Based Chemotherapies

(2009) Joseph Ciccolini et al.   JOURNAL OF CLINICAL ONCOLOGY

Simultaneous quantification of 2′,2′-difluorodeoxycytidine and 2′,2′-difluorodeoxyuridine nucleosides and nucleotides in white blood cells using porous graphitic carbon chromatography coupled with tandem mass spectrometry

(2009) Robert S. Jansen et al.   RAPID COMMUNICATIONS IN MASS SPECTROMETRY

Does saturable formation of gemcitabine triphosphate occur in patients?

(2008) Lai-San Tham et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients

(2008) C. Tibaldi et al.   CLINICAL CANCER RESEARCH

Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients

(2008) Ross A. Soo et al.   LUNG CANCER

Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate

(2007) Xuemin Jiang et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY